首页> 外文期刊>Drug Design, Development and Therapy >Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial
【24h】

Quetiapine versus haloperidol in the treatment of delirium: a double-blind, randomized, controlled trial

机译:喹硫平与氟哌啶醇治疗del妄:一项双盲,随机,对照试验

获取原文
       

摘要

Background: Atypical antipsychotic drugs may have low propensity to induce extrapyramidal side effects in delirious patients. This study aimed to compare the efficacy and tolerability between quetiapine and haloperidol in controlling delirious behavior. Methods: A 7-day prospective, double-blind, randomized controlled trial was conducted from June 2009 to April 2011 in medically ill patients with delirium. Measures used for daily assessment included the Delirium Rating Scale-revised-98 (DRS-R-98) and total sleep time. The Clinical Global Impression, Improvement (CGI–I) and the Modified (nine-item) Simpson–Angus Scale were applied daily. The primary outcome was the DRS-R-98 severity scores. The data were analyzed on an intention-to-treat basis. Results: Fifty-two subjects (35 males and 17 females) were randomized to receive 25–100 mg/day of quetiapine (n = 24) or 0.5–2.0 mg/day of haloperidol (n = 28). Mean (standard deviation) doses of quetiapine and haloperidol were 67.6 (9.7) and 0.8 (0.3) mg/day, respectively. Over the trial period, means (standard deviation) of the DRS-R-98 severity scores were not significantly different between the quetiapine and haloperidol groups (-22.9 [6.9] versus -21.7 [6.7]; P = 0.59). The DRS-R-98 noncognitive and cognitive subscale scores were not significantly different. At end point, the response and remission rates, the total sleep time, and the Modified (nine-item) Simpson–Angus scores were also not significantly different between groups. Hypersomnia was common in the quetiapine-treated patients (33.3%), but not significantly higher than that in the haloperidol-treated group (21.4%). Limitations: Patients were excluded if they were not able to take oral medications, and the sample size was small. Conclusion: Low-dose quetiapine and haloperidol may be equally effective and safe for controlling delirium symptoms. Clinical trials registration number: clinicaltrials.gov NCT00954603.
机译:背景:非典型抗精神病药在精神错乱患者中诱发锥体外系副作用的倾向可能较低。这项研究旨在比较喹硫平和氟哌啶醇在控制精神错乱行为方面的功效和耐受性。方法:2009年6月至2011年4月,对患有medical妄的内科疾病患者进行了为期7天的前瞻性,双盲,随机对照试验。日常评估所用的措施包括:Delirium评定量表修订版98(DRS-R-98)和总睡眠时间。每天应用临床总体印象,改善(CGI–I)和修正的(九项)辛普森–安格斯量表。主要结果是DRS-R-98严重程度评分。对数据进行了意向性分析。结果:52名受试者(35名男性和17名女性)被随机分配接受25–100 mg /天的喹硫平(n = 24)或0.5–2.0 mg /天的氟哌啶醇(n = 28)。喹硫平和氟哌啶醇的平均剂量(标准差)分别为67.6(9.7)和0.8(0.3)mg /天。在整个试验期间,喹硫平和氟哌啶醇组之间DRS-R-98严重程度评分的平均值(标准差)没有显着差异(-22.9 [6.9]与-21.7 [6.7]; P = 0.59)。 DRS-R-98的非认知和认知分量表得分无显着差异。在终点,两组之间的反应和缓解率,总睡眠时间以及改良的(九项)辛普森-安格斯评分也无显着差异。在喹硫平治疗的患者中常有失眠现象(33.3%),但与氟哌啶醇治疗的组(21.4%)相比却不明显。局限性:如果患者不能口服药物,且样本量较小,则将其排除在外。结论:小剂量喹硫平和氟哌啶醇在控制del妄症状方面同样有效和安全。临床试验注册号:clinicaltrials.gov NCT00954603。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号